IP Library › Patent Application 15341870
Patent Application
App. No. 15/341,870

IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/341,870
Abstract

The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor C form a heteromeric receptor complex that is biologically active. Antagonists of the IL-17RA-IL-17RB heteromeric receptor complex are disclosed, as well as various methods of use.

Claims (15)

1 . A method of inhibiting IL-17RA-IL-17RB heteromeric receptor complex activation, comprising exposing a cell expressing at least IL-17RA and IL-17RB to an IL-17RA-IL-17RB antagonist such that activation of an IL-17RA-IL-17RB heteromeric receptor complex by IL-25 is partially or fully inhibited.

2 . The method of claim 1 , wherein the IL-17RA-IL-17RB antagonist is an antigen binding protein.

3 . The method of claim 2 , wherein the antigen binding protein binds the IL-17RA-IL-17RB heteromeric receptor complex or a subunit thereof.

4 . The method of claim 1 , wherein formation of an IL-17RA-IL-17RB heteromeric receptor complex is partially or fully inhibited.

5 . The method of claim 1 , wherein release of at least one proinflammatory mediator is partially or fully inhibited.

6 . The method of claim 5 , wherein the proinflammatory mediator is selected from the group consisting of: IL-5, IL-6, IL-8, IL-13, CXCL 1, CXCL2, GM-CSF, G-CSF, M-CSF, IL-1β, TNFα, RANK-L, LIF, PGE2, IL-12, MMP3, MMP9, GROα, and NO.

7 . A method of inhibiting IL-17RA-IL-17RB heteromeric receptor complex activation in vivo, comprising exposing a cell expressing at least IL-17RA and IL-17RB to an IL-17RA-IL-17RB antagonist such that activation of an IL-17RA-IL-17RB heteromeric receptor complex by IL-25 is partially or fully inhibited.

8 . The method of claim 7 , wherein the IL-17RA-IL-17RB antagonist is an antigen binding protein.

9 . The method of claim 8 , wherein the antigen binding protein binds the IL-17RA-IL-17RB heteromeric receptor complex or a subunit thereof.

10 . The method of claim 7 , wherein formation of an IL-17RA-IL-17RB heteromeric receptor complex is partially or fully inhibited.

11 . The method of claim 7 , wherein release of at least one proinflammatory mediator is partially or fully inhibited.

12 . The method of claim 11 , wherein the proinflammatory mediator is selected from the group consisting of: IL-5, IL-6, IL-8, IL-13, CXCL1, CXCL2, GM-CSF, G-CSF, M-CSF, IL-1β, TNFα, RANK-L, LIF, PGE2, IL-12, MMP3, MMP9, GROα, and NO.

13 . The method of claim 7 , wherein the IL-17RA-IL-17RB antagonist is administered to an individual afflicted with an autoimmune or inflammatory disease.

14 . The method of claim 13 , wherein the autoimmune or inflammatory disease is selected from the group consisting of Acute Respiratory Disorder Syndrome (ARDS), respiratory distress syndrome, bronchitis, and airway hyperresponsiveness associated with viral-induced conditions such as respiratory syncytial virus (RSV), parainfluenza virus (PIV}, rhinovirus (RV) and adenovirus.

15 . The method of claim 13 , wherein the IL-17RA-IL-17RB antagonist partially or fully reduces or ameliorates the signs and/or symptoms of the autoimmune or inflammatory disease.